This article is more than 5 years old. Information may no longer be current.

CLS-TA trial shows reduction of retinal thickness in noninfectious uveitis

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Administration of CLS-TA in patients with noninfectious uveitis resulted in significant reductions in baseline retinal thickness, according to a press release from Clearside Biomedical, which outlined data from the PEACHTREE trial released at the American Society of Retina Specialists annual meeting in Vancouver, British Columbia.

At least 50% of patients in the CLS-TA arm of the trial had resolution of macular edema at every visit and were able to read at least 70 ETDRS letters, the release said. Eighty-five percent of patients in the treatment arm of the trial did not require rescue therapy.

Suprachoroidal CLS-TA is a suspension of triamcinolone acetonide administered to the back of the eye via the suprachoroidal space.

Initial data of the randomized, masked, sham-controlled trial, which were announced in March, showed 47% of patients who received suprachoroidal CLS-TA gained at least 15 letters in best corrected visual acuity from baseline to week 24 (P < .001) compared with 15% of patients who underwent a sham procedure.